-
1
-
-
0030976004
-
Cognitive enhancement therapy for Alzheimer's disease: The way forward
-
Parnetti L, Senin U, Mecocci P. Cognitive enhancement therapy for Alzheimer's disease: the way forward. Drugs 1997; 53:752-68.
-
(1997)
Drugs
, vol.53
, pp. 752-768
-
-
Parnetti, L.1
Senin, U.2
Mecocci, P.3
-
2
-
-
0029917179
-
Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease
-
Sramek JJ, Anand R, Wardle TS et al. Safety/tolerability trial of SDZ ENA 713 in patients with probable Alzheimer's disease. Life Sci. 1996; 58:1201-7.
-
(1996)
Life Sci.
, vol.58
, pp. 1201-1207
-
-
Sramek, J.J.1
Anand, R.2
Wardle, T.S.3
-
3
-
-
0028448282
-
Tacrine: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease
-
Wagstaff AJ, McTavish D. Tacrine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease. Drugs Aging. 1994; 4:510-40.
-
(1994)
Drugs Aging
, vol.4
, pp. 510-540
-
-
Wagstaff, A.J.1
McTavish, D.2
-
4
-
-
0031904626
-
Alzheimer's disease: Clinical features and pharmacologic management
-
Franks AS, Rawls WN. Alzheimer's disease: clinical features and pharmacologic management. Am J Manag Care. 1998; 4:595-604.
-
(1998)
Am J Manag Care
, vol.4
, pp. 595-604
-
-
Franks, A.S.1
Rawls, W.N.2
-
5
-
-
0013163515
-
-
New York: Roerig, Division of Pfizer, Inc.
-
Aricept package insert. New York: Roerig, Division of Pfizer, Inc.; 1996.
-
(1996)
Aricept Package Insert
-
-
-
6
-
-
0027141935
-
Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects
-
Ohnishi A, Mihara M, Kamakura H et al. Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy young and elderly subjects. J Clin Pharmacol. 1993; 33:1086-91.
-
(1993)
J Clin Pharmacol.
, vol.33
, pp. 1086-1091
-
-
Ohnishi, A.1
Mihara, M.2
Kamakura, H.3
-
7
-
-
0029915565
-
Metrifonate induces cholinesterase inhibition exclusively via slow release of dichlorvos
-
Hinz VC, Grewig S, Schmidt BH. Metrifonate induces cholinesterase inhibition exclusively via slow release of dichlorvos. Neurochem Res. 1996; 21:331-7.
-
(1996)
Neurochem Res.
, vol.21
, pp. 331-337
-
-
Hinz, V.C.1
Grewig, S.2
Schmidt, B.H.3
-
9
-
-
0024246154
-
Alzheimer's Disease Assessment Scale (ADAS)
-
Mohs RC, Cohen L. Alzheimer's Disease Assessment Scale (ADAS). Psychopharmacol Bull. 1988; 24:627-8.
-
(1988)
Psychopharmacol Bull.
, vol.24
, pp. 627-628
-
-
Mohs, R.C.1
Cohen, L.2
-
10
-
-
0028114429
-
The Clinician Interview-Based Impression (CIBI): A clinician's global change rating scale in Alzheimer's disease
-
Knopman DS, Knapp MJ, Gracon SI et al. The Clinician Interview-Based Impression (CIBI): a clinician's global change rating scale in Alzheimer's disease. Neurology. 1994; 44:2315-21.
-
(1994)
Neurology
, vol.44
, pp. 2315-2321
-
-
Knopman, D.S.1
Knapp, M.J.2
Gracon, S.I.3
-
11
-
-
0016823810
-
"Mini-Mental State": A practical method for grading the cognitive state of patients for the clinician
-
Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-98.
-
(1975)
J Psychiatr Res.
, vol.12
, pp. 189-198
-
-
Folstein, M.F.1
Folstein, S.E.2
McHugh, P.R.3
-
12
-
-
0026792979
-
A controlled trial of tacrine in Alzheimer's disease
-
The Tacrine Study Group
-
Farlow M, Gracon SI, Hershey LA et al. A controlled trial of tacrine in Alzheimer's disease. The Tacrine Study Group. JAMA. 1992; 268:2523-9.
-
(1992)
JAMA
, vol.268
, pp. 2523-2529
-
-
Farlow, M.1
Gracon, S.I.2
Hershey, L.A.3
-
13
-
-
10244259208
-
The efficacy and safety of donepezil in patients with Alzheimer's disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial
-
The Donepezil Study Group
-
Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia. 1996; 7:293-303.
-
(1996)
Dementia
, vol.7
, pp. 293-303
-
-
Rogers, S.L.1
Friedhoff, L.T.2
-
14
-
-
0032513106
-
Safety and tolerability of metrifonate in patients with Alzheimer's disease: Results of a maximum tolerated dose study
-
Cutler NR, Jhee SS, Cyrus P et al. Safety and tolerability of metrifonate in patients with Alzheimer's disease: results of a maximum tolerated dose study. Life Sci. 1998; 62:1433-41.
-
(1998)
Life Sci.
, vol.62
, pp. 1433-1441
-
-
Cutler, N.R.1
Jhee, S.S.2
Cyrus, P.3
-
15
-
-
0031883716
-
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
-
Rogers SL, Farlow MR, Doody RS et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology. 1998; 50:136-45.
-
(1998)
Neurology
, vol.50
, pp. 136-145
-
-
Rogers, S.L.1
Farlow, M.R.2
Doody, R.S.3
-
16
-
-
0029766994
-
Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's disease: An overview
-
Anand R, Gharabawi G, Enz A. Efficacy and safety results of the early phase studies with Exelon (ENA-713) in Alzheimer's disease: an overview. J Drug Dev Clin Pract. 1996; 8:109-16.
-
(1996)
J Drug Dev Clin Pract.
, vol.8
, pp. 109-116
-
-
Anand, R.1
Gharabawi, G.2
Enz, A.3
-
17
-
-
0031842292
-
Metrifonate treatment of the cognitive deficits of Alzheimer's disease
-
Cummings JL, Cyrus PA, Bieber F et al. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Neurology. 1998; 50:1214-21.
-
(1998)
Neurology
, vol.50
, pp. 1214-1221
-
-
Cummings, J.L.1
Cyrus, P.A.2
Bieber, F.3
-
21
-
-
0029914548
-
Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study
-
Kaufer DI, Cummings JL, Christine D. Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study. J Geriatr Psychiatry Neurol. 1996; 9:1-6.
-
(1996)
J Geriatr Psychiatry Neurol.
, vol.9
, pp. 1-6
-
-
Kaufer, D.I.1
Cummings, J.L.2
Christine, D.3
-
22
-
-
0001033736
-
The efficacy of metrifonate in improving the behavioral disturbances of Alzheimer's disease patients
-
Minneapolis; Apr 25-May 3
-
Cummings JL, Cyrus PA, Ruzicka BB et al. The efficacy of metrifonate in improving the behavioral disturbances of Alzheimer's disease patients. Paper presented at American Academy of Neurology 1998 Annual Meeting. Minneapolis; 1998 Apr 25-May 3.
-
(1998)
American Academy of Neurology 1998 Annual Meeting
-
-
Cummings, J.L.1
Cyrus, P.A.2
Ruzicka, B.B.3
|